ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMGastos comerciales, generales y administrativos28.85 M30.5 M33.49 M36.52 M41.8 M142.32 MInvestigación y desarrollo6.7 M6.09 M6.85 M7.57 M12.38 M32.88 MBeneficio operativo2.02 M-1.66 M1.67 M1.91 M-9.77 M-7.85 MTotal de ingresos no operativos-1.57 M-2.17 M-1.09 M-1.2 M-3.38 M-7.85 MGastos por intereses, netos de intereses capitalizados1.8 M2.25 M1.98 M1.76 M1.72 M7.7 MIngresos no operativos, una vez deducidos los gastos por intereses-3.32 M-4.39 M-3.25 M-2.99 M-5.1 M-15.72 MIngresos/gastos extraordinarios-45 K-37 K179 K25 K0167 KBeneficio antes de impuestos-1.35 M-6.08 M-1.4 M-1.05 M-14.87 M-23.41 MParticipación en los beneficios——————Impuestos000000Participación minoritaria——————Otros ingresos/gastos después de impuestos——————Beneficio neto antes de actividades interrumpidas450 K-3.83 M579 K708 K-13.16 M-15.7 MOperaciones suspendidas——————Beneficio neto450 K-3.83 M579 K708 K-13.16 M-15.7 MAjuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas450 K-3.83 M579 K708 K-13.16 M-15.7 MBeneficio básico por acción0-0.080.010.02-0.29-0.34Beneficio por acción diluido0-0.080.010.01-0.28-0.34Número medio de acciones ordinarias44.26 M45.2 M46.06 M46.49 M46.05 M183.81 MAcciones diluidas44.26 M45.2 M47.98 M49.09 M46.05 M188.32 MEBITDA15.48 M13.69 M17.97 M17.64 M7.36 M56.67 MEBIT13.85 M11.97 M16.32 M16 M5.72 M50.01 MCosto de los ingresos11.83 M13.63 M14.64 M14.09 M15.49 M57.85 MOtros costes de producción——————Amortización y depreciación (flujo de caja)1.64 M1.73 M1.66 M1.64 M1.63 M6.66 M
Axogen Inc
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use.